Literature DB >> 23636772

Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.

Amy McCurley1, Adam McGraw, Dafina Pruthi, Iris Z Jaffe.   

Abstract

The mineralocorticoid receptor (MR), a member of the steroid receptor family, regulates blood pressure by mediating the effects of the hormone aldosterone on renal sodium handling. In recent years, it has become clear that MR is expressed in vascular smooth muscle cells (SMCs), and interest has grown in understanding the direct role of SMC MR in regulating vascular function. This interest stems from multiple clinical studies where MR inhibitor treatment reduced the incidence of cardiovascular events and mortality. This review summarizes the most recent advances in our understanding of SMC MR in regulating normal vascular function and in promoting vascular disease. Many new studies suggest a role for SMC MR activation in stimulating vascular contraction and contributing to vessel inflammation, fibrosis, and remodeling. These detrimental vascular effects of MR activation appear to be independent of changes in blood pressure and are synergistic with the presence of endothelial dysfunction or damage. Thus, in humans with underlying cardiovascular disease or cardiovascular risk factors, SMC MR activation may promote hypertension, atherosclerosis, and vascular aging. Further exploration of the molecular mechanisms for the effects of SMC MR activation has the potential to identify novel therapeutic targets to prevent or treat common cardiovascular disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636772      PMCID: PMC3769467          DOI: 10.1007/s00424-013-1282-4

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  97 in total

1.  Distinguishing the antihypertensive and electrolyte effects of eplerenone.

Authors:  D G Levy; R Rocha; J W Funder
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences.

Authors:  David Sanz-Rosa; M Pilar Oubiña; Eva Cediel; Natalia De las Heras; Paloma Aragoncillo; Gloria Balfagón; Victoria Cachofeiro; Vicente Lahera
Journal:  Antioxid Redox Signal       Date:  2005 Sep-Oct       Impact factor: 8.401

4.  Vascular hypertrophy and remodeling in secondary hypertension.

Authors:  D Rizzoni; E Porteri; M Castellano; G Bettoni; M L Muiesan; P Muiesan; S M Giulini; E Agabiti-Rosei
Journal:  Hypertension       Date:  1996-11       Impact factor: 10.190

5.  Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries.

Authors:  M R Ward; P Kanellakis; D Ramsey; J Funder; A Bobik
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

Review 6.  Signal transduction and regulation in smooth muscle.

Authors:  A P Somlyo; A V Somlyo
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

7.  Rapid aldosterone signaling and vascular reactivity: relax or don't do it.

Authors:  Jane A Leopold
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

Review 8.  Blood pressure control in the elderly: can you have too much of a good thing?

Authors:  David J Hyman; George E Taffet
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

9.  Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.

Authors:  James M Luther; Pengcheng Luo; Zuofei Wang; Samuel E Cohen; Hyung-Suk Kim; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

10.  Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.

Authors:  Amy McCurley; Paulo W Pires; Shawn B Bender; Mark Aronovitz; Michelle J Zhao; Daniel Metzger; Pierre Chambon; Michael A Hill; Anne M Dorrance; Michael E Mendelsohn; Iris Z Jaffe
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

View more
  21 in total

Review 1.  Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Authors:  Nicholas C Bene; Pilar Alcaide; Henry H Wortis; Iris Z Jaffe
Journal:  Steroids       Date:  2014-04-21       Impact factor: 2.668

Review 2.  The pathophysiology of hypertension in patients with obesity.

Authors:  Vincent G DeMarco; Annayya R Aroor; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2014-04-15       Impact factor: 43.330

3.  Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone.

Authors:  Miranda E Good; Yu-Hsin Chiu; Ivan K H Poon; Christopher B Medina; Joshua T Butcher; Suresh K Mendu; Leon J DeLalio; Alexander W Lohman; Norbert Leitinger; Eugene Barrett; Ulrike M Lorenz; Bimal N Desai; Iris Z Jaffe; Douglas A Bayliss; Brant E Isakson; Kodi S Ravichandran
Journal:  Circ Res       Date:  2017-12-13       Impact factor: 17.367

4.  Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure.

Authors:  Katelee Barrett Mueller; Shawn B Bender; Kwangseok Hong; Yan Yang; Mark Aronovitz; Frederic Jaisser; Michael A Hill; Iris Z Jaffe
Journal:  Hypertension       Date:  2015-09-08       Impact factor: 10.190

Review 5.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

6.  Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats.

Authors:  Shun Watanabe; Takayuki Matsumoto; Makoto Ando; Tsuyuki Adachi; Shota Kobayashi; Maika Iguchi; Miki Takeuchi; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2016-05-12       Impact factor: 3.657

7.  Mineralocorticoid receptor antagonists improve membrane integrity independent of muscle force in muscular dystrophy.

Authors:  J Spencer Hauck; Jeovanna Lowe; Neha Rastogi; Kevin E McElhanon; Jennifer M Petrosino; Kyra K Peczkowski; Ashlee N Chadwick; Jonathan G Zins; Federica Accornero; Paul M L Janssen; Noah L Weisleder; Jill A Rafael-Fortney
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

Review 8.  Arterial Stiffness in Hypertension: an Update.

Authors:  Korshie Dumor; Michael Shoemaker-Moyle; Ravi Nistala; Adam Whaley-Connell
Journal:  Curr Hypertens Rep       Date:  2018-07-04       Impact factor: 5.369

Review 9.  Cellular mechanisms underlying obesity-induced arterial stiffness.

Authors:  Annayya R Aroor; Guanghong Jia; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-11-22       Impact factor: 3.619

10.  Maternal food restriction modulates cerebrovascular structure and contractility in adult rat offspring: effects of metyrapone.

Authors:  Lara M Durrant; Omid Khorram; John N Buchholz; William J Pearce
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-29       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.